NCT03050294View on ClinicalTrials.gov

Evaluating Treatment Resistant Dermatitis TaroIIR

PHASE4CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 1, 2017

Primary Completion Date

June 1, 2017

Study Completion Date

June 1, 2017

Conditions
Atopic DermatitisPsoriasis
Interventions
BEHAVIORAL

Phone calls

Phone calls twice daily

DRUG

Desoximetasone 0.25% spray

Desoximetasone 0.25% spray applied twice daily

Trial Locations (1)

27157

Wake Forest University Health Sciences Department of Dermatology, Winston-Salem

All Listed Sponsors
lead

Wake Forest University Health Sciences

OTHER

NCT03050294 - Evaluating Treatment Resistant Dermatitis TaroIIR | Biotech Hunter | Biotech Hunter